Company research
Candel Therapeutics, Inc.
CIK 1841387Updated Sep 26, 2026
SecurityCADL · NASDAQ · equity
CADL price & chart
Loading TradingView…
NASDAQ:CADL on TradingView ↗About the company
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the
In the news
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 125,195,000Source | 106,866,000Source | 41,201,000Source | 77,691,000Source |
| Property, Plant and Equipment, NetUSD | 1,642,000Source | 2,191,000Source | 3,206,000Source | 4,424,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 119,731,000Source | 102,654,000Source | 35,413,000Source | 70,058,000Source |
| Assets, CurrentUSD | 121,389,000Source | 103,804,000Source | 36,797,000Source | 71,945,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,658,000Source | 1,150,000Source | 1,384,000Source | 1,887,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,661,000Source | 542,000Source | 816,000Source | 1,056,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 73,273,000Source | 40,539,000Source | 28,456,000Source | 29,977,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 550,000Source | 469,000Source | 290,000Source | 290,000Source |
| Retained Earnings (Accumulated Deficit)USD | -230,387,000Source | -192,205,000Source | -137,028,000Source | -99,089,000Source |
| Stockholders' Equity Attributable to ParentUSD | 51,922,000Source | 66,327,000Source | 12,745,000Source | 47,714,000Source |
| Additional Paid in Capital, Common StockUSD | 282,207,000Source | 258,511,000Source | 149,931,000Source | 146,961,000Source |
| Liabilities and EquityUSD | 125,195,000Source | 106,866,000Source | 41,201,000Source | 77,691,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,997,000Source | 37,529,000Source | 14,184,000Source | 5,615,000Source |
| Operating Lease, Liability, CurrentUSD | 445,000Source | 566,000Source | 513,000Source | 464,000Source |
| Accounts Payable, CurrentUSD | 1,129,000Source | 237,000Source | 422,000Source | 380,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,459,000Source | 407,000Source | 973,000Source | 1,486,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,334,000Source | 5,113,000Source | 4,356,000Source | 4,723,000Source |
| Deferred Revenue, NoncurrentUSD | 89,000Source | — | — | 144,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 9,895,000Source | 8,893,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 1,733,000Source | 11,632,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -38,182,000Source | -55,177,000Source | -37,939,000Source | -18,794,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 778,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,817,000Source | 5,312,000Source | 3,091,000Source | 2,307,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 802,000Source | -185,000Source | 45,000Source | -1,213,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -38,311,000Source | -27,023,000Source | -34,244,000Source | -31,419,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -560,000Source | -16,000Source | -280,000Source | -1,297,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 587,000Source | 16,000Source | 457,000Source | 1,297,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 121,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 56,098,000Source | 94,280,000Source | -121,000Source | 19,974,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 17,227,000Source | 67,241,000Source | -34,645,000Source | -12,742,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 120,147,000Source | 102,920,000Source | 35,679,000Source | 70,324,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,280,000Source | 1,795,000Source | 2,148,000Source | 1,152,000Source |
| Income Taxes Paid, NetUSD | — | — | — | 183,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 3,817,000Source | 5,312,000Source | 3,091,000Source | 2,307,000Source |
| DepreciationUSD | 845,000Source | 990,000Source | 960,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | -306,000Source | — | -79,000Source | — |
| General and Administrative ExpenseUSD | 17,770,000Source | 14,057,000Source | 13,885,000Source | 14,060,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 2,119,000Source | 2,090,000Source | — | — |
| Investment Income, InterestUSD | — | — | 2,081,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -38,182,000Source | -55,177,000Source | -37,939,000Source | -18,794,000Source |
| Nonoperating Income (Expense)USD | 10,084,000Source | -21,806,000Source | 452,000Source | 15,928,000Source |
| Operating ExpensesUSD | 48,266,000Source | 33,371,000Source | 38,391,000Source | 34,847,000Source |
| Proceeds from Stock Options ExercisedUSD | 516,000Source | 1,689,000Source | — | 64,000Source |
| Restructuring CostsUSD | — | — | 700,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 125,000Source |
| Operating Income (Loss)USD | -48,266,000Source | -33,371,000Source | -38,391,000Source | -34,722,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -38,182,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -38,182,000Source | -55,177,000Source | -37,939,000Source | -18,794,000Source |
| Earnings Per Share, BasicUSD per share | -0.72Source | -1.74Source | -1.31Source | -0.65Source |
| Earnings Per Share, DilutedUSD per share | -0.72Source | -1.74Source | -1.31Source | -0.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 52,958,644Source | 31,675,076Source | 28,935,289Source | 28,823,480Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 52,958,644Source | 31,675,076Source | 28,935,289Source | 28,823,480Source |
| Interest Expense (non-operating)USD | 2,119,000Source | 2,090,000Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 800,000Source |
| General and Administrative ExpenseUSD | 17,770,000Source | 14,057,000Source | 13,885,000Source | 14,060,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -38,182,000Source | — | — | — |
| Interest and Other IncomeUSD | 3,915,000Source | 1,086,000Source | — | — |
| Interest ExpenseUSD | 2,119,000Source | -2,090,000Source | 2,595,000Source | — |
| Investment Income, InterestUSD | — | — | 2,081,000Source | — |
| Investment Income, NetUSD | — | — | — | -490,000Source |
| Labor and Related ExpenseUSD | 7,624,000Source | 6,831,000Source | — | — |
| Nonoperating Income (Expense)USD | 10,084,000Source | -21,806,000Source | 452,000Source | 15,928,000Source |
| Operating ExpensesUSD | 48,266,000Source | 33,371,000Source | 38,391,000Source | 34,847,000Source |
| Other General and Administrative ExpenseUSD | 1,848,000Source | 1,963,000Source | — | — |
| Research and Development ExpenseUSD | 30,496,000Source | 19,314,000Source | 24,506,000Source | 20,787,000Source |
| Restructuring CostsUSD | — | — | 700,000Source | — |
Filing attachments
cadl-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 cadl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors • Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing mul…
Read attachment ↗d738484dex991.htm · 8-K · 2026-09-09
EX-99.1 2 d738484dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tipping the balance in favor of the immune system to fight cancer NASDAQ: CADL Corporate Presentation | September 2026 © © 2026 2026 by by C Ca an ndel del T Ther hera ap peu eut ti ic cs s Forward Looking Statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Presentation, i…
Read attachment ↗cadl-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 cadl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights • Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026 • Pivotal phase 3 clinical data published in The Lancet Oncology demonstrated a statistically significant improvement in disease-free survival with aglatimagene plus st…
Read attachment ↗d106447dex991.htm · 8-K · 2026-05-15
EX-99.1 2 d106447dex991.htm EX-99.1 EX-99.1 AUA Investor Call Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer May 15, 2026 NASDAQ: CADL Exhibit 99.1 Forward-looking statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Presentation, including express or implied statements regarding our str…
Read attachment ↗d106447dex992.htm · 8-K · 2026-05-15
EX-99.2 3 d106447dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in…
Read attachment ↗cadl-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 cadl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights • Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 • Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer • Company…
Read attachment ↗